Perceptive Advisors LLC increased its holdings in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 3.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,809,015 shares of the company’s stock after buying an additional 55,000 shares during the quarter. Dova Pharmaceuticals comprises 1.7% of Perceptive Advisors LLC’s portfolio, making the stock its 15th largest holding. Perceptive Advisors LLC owned about 0.07% of Dova Pharmaceuticals worth $52,099,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. The Manufacturers Life Insurance Company grew its holdings in Dova Pharmaceuticals by 702.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 4,756 shares of the company’s stock worth $137,000 after buying an additional 4,163 shares in the last quarter. California State Teachers Retirement System bought a new position in Dova Pharmaceuticals in the 3rd quarter worth approximately $202,000. Schwab Charles Investment Management Inc. bought a new position in Dova Pharmaceuticals in the 3rd quarter worth approximately $241,000. Virtus Fund Advisers LLC bought a new position in Dova Pharmaceuticals in the 4th quarter worth approximately $318,000. Finally, Deutsche Bank AG grew its holdings in Dova Pharmaceuticals by 139.2% in the 4th quarter. Deutsche Bank AG now owns 11,748 shares of the company’s stock worth $337,000 after buying an additional 6,836 shares in the last quarter. 26.05% of the stock is owned by institutional investors and hedge funds.
Dova Pharmaceuticals Inc (DOVA) opened at $29.62 on Monday. Dova Pharmaceuticals Inc has a one year low of $16.98 and a one year high of $37.00.
A number of brokerages recently issued reports on DOVA. BidaskClub raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Jefferies Group increased their price objective on Dova Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a report on Tuesday, November 28th. Finally, Zacks Investment Research lowered Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $32.75.
TRADEMARK VIOLATION NOTICE: “Perceptive Advisors LLC Increases Stake in Dova Pharmaceuticals Inc (DOVA)” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3257871/perceptive-advisors-llc-increases-stake-in-dova-pharmaceuticals-inc-dova.html.
Dova Pharmaceuticals Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Want to see what other hedge funds are holding DOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dova Pharmaceuticals Inc (NASDAQ:DOVA).
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.